Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
Verrica Pharmaceuticals Inc. is an innovative clinical-stage medical dermatology c...
Verrica Pharmaceuticals Inc. is an innovative c...
Elevate is the first of its kind, a line of high-performance nutritional supplemen...
Elevate is the first of its kind, a line of hig...
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developi...
Urovant Sciences is a clinical-stage biopharmac...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...
Simulations Plus, Inc. is the leading developer...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Join the National Investor Network and get the latest information with your interests in mind.